CompareMarketResearchRequest a sample
Home / Healthcare / Liposome

Healthcare · Market report

Liposome Market Size, Share and Forecast 2026-2036

The global liposome market is worth USD 5.2 bn in 2026 and is forecast to reach USD 11.1 bn by 2036, growing at a 8.0% CAGR. United States is the largest country market and Anticancer is the largest by drug class segment.

USD 5.2 bnMarket size 2026
USD 11.1 bnForecast 2036
8.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global liposome market is worth USD 5.2 bn in 2026 and is forecast to reach USD 11.1 bn by 2036, growing at a 8.0% CAGR. United States is the largest country market and Anticancer is the largest by drug class segment.

ScopePharmaceutical products delivered in liposomes, lipid vesicles that carry a drug: liposomal doxorubicin, amphotericin B, irinotecan, bupivacaine, vincristine and similar injectables.
IndustryHealthcare
Value 2025USD 4.8 bn
Value 2026USD 5.2 bn
Value 2036USD 11.1 bn
CAGR 2026-20368.0%
Volume 202612.8 million doses
Volume 203626.4 million doses
Average price 2026USD 402 per dose
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Liposome market size and forecast, 2026-2036

Exhibit 1The global liposome market is forecast to grow from USD 5.2 bn in 2026 to USD 11.1 bn by 2036, more than doublingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 8.0%
Liposome market value, 2025 to 2036Market value by year. 2025: USD 4.8 bn; 2026: USD 5.2 bn; 2027: USD 5.6 bn; 2028: USD 6.0 bn; 2029: USD 6.5 bn; 2030: USD 7.0 bn; 2031: USD 7.6 bn; 2032: USD 8.2 bn; 2033: USD 8.8 bn; 2034: USD 9.6 bn; 2035: USD 10.3 bn; 2036: USD 11.1 bn. Compound annual growth rate 2026 to 2036: 8.0%.20255.2 bn20267.6 bn203111.1 bn20368.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 5.2 bn
2027USD 5.6 bn
2028USD 6.0 bn
2029USD 6.5 bn
2030USD 7.0 bn
2031USD 7.6 bn
2032USD 8.2 bn
2033USD 8.8 bn
2034USD 9.6 bn
2035USD 10.3 bn
2036USD 11.1 bn

Liposome market segmentation

By drug class

Exhibit 2Anticancer is the largest segment by drug class, with 52.0% of 2026 revenueEstimated share of 2026 global revenue, by drug class
Liposome market share by drug class, 2026Share of 2026 revenue by drug class. Anticancer: 52.0%; Antifungal: 19.0%; Pain management: 16.0%; Other: 13.0%.Anticancer52.0%Antifungal19.0%Pain management16.0%Other13.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Anticancer52.0%55.4%USD 2.7 bn8.7%
Antifungal19.0%15.3%USD 980 mn5.7%
Pain management16.0%14.8%USD 826 mn7.2%
Other13.0%14.5%USD 671 mn9.2%

By route

Exhibit 3Intravenous adds the most revenue by route, growing from USD 3.7 bn in 2026 to USD 7.7 bn by 2036Estimated revenue in USD by route, 2026 and 2036 forecast
Liposome market by route, 2026 and 2036Revenue by route in 2026 and 2036. Intravenous: USD 3.7 bn in 2026, USD 7.7 bn in 2036, change +108%; Inhaled, topical and other: USD 619 mn in 2026, USD 1.8 bn in 2036, change +187%; Local injection and infiltration: USD 826 mn in 2026, USD 1.6 bn in 2036, change +99%.20262036 forecastChangeIntravenous+108%3.7 bn7.7 bnInhaled, topical and other+187%619 mn1.8 bnLocal injection and infiltration+99%826 mn1.6 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Intravenous72.0%69.4%USD 3.7 bn7.6%
Local injection and infiltration16.0%14.7%USD 826 mn7.1%
Inhaled, topical and other12.0%15.9%USD 619 mn11.1%

By lipid composition

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Phospholipid liposomes44.0%41.0%USD 2.3 bn7.2%
PEGylated liposomes26.0%27.0%USD 1.3 bn8.4%
Cationic liposomes14.0%16.0%USD 722 mn9.4%
Ligand-targeted liposomes16.0%16.0%USD 826 mn8.0%

By application

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Oncology42.0%40.0%USD 2.2 bn7.5%
Infectious disease18.0%16.0%USD 929 mn6.7%
Vaccines and gene delivery14.0%20.0%USD 722 mn11.9%
Pain management12.0%11.0%USD 619 mn7.1%
Cosmeceutical and nutrition14.0%13.0%USD 722 mn7.2%

By development stage

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Marketed products62.0%55.0%USD 3.2 bn6.7%
Clinical stage30.0%33.0%USD 1.5 bn9.0%
Preclinical stage8.0%12.0%USD 413 mn12.5%

Top 25 countries for liposome by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 89.5% of 2026 revenue and the 25 countries below together hold 97.5%.

Exhibit 4United States is the largest country market at USD 2.4 bn in 2026, and the three largest countries hold 62.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Liposome market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 2.4 bn, 46.0%; Japan: USD 464 mn, 9.0%; China: USD 361 mn, 7.0%; Germany: USD 310 mn, 6.0%; France: USD 258 mn, 5.0%; United Kingdom: USD 206 mn, 4.0%; Italy: USD 206 mn, 4.0%; Spain: USD 155 mn, 3.0%; Canada: USD 155 mn, 3.0%; South Korea: USD 129 mn, 2.5%.United States2.4 bn 46.0%Japan464 mn 9.0%China361 mn 7.0%Germany310 mn 6.0%France258 mn 5.0%United Kingdom206 mn 4.0%Italy206 mn 4.0%Spain155 mn 3.0%Canada155 mn 3.0%South Korea129 mn 2.5%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 2.4 bn46.0%USD 5.0 bn7.8%
2JapanUSD 464 mn9.0%USD 813 mn5.8%
3ChinaUSD 361 mn7.0%USD 1.1 bn12.2%
4GermanyUSD 310 mn6.0%USD 657 mn7.8%
5FranceUSD 258 mn5.0%USD 524 mn7.3%
6United KingdomUSD 206 mn4.0%USD 434 mn7.7%
7ItalyUSD 206 mn4.0%USD 412 mn7.2%
8SpainUSD 155 mn3.0%USD 312 mn7.3%
9CanadaUSD 155 mn3.0%USD 323 mn7.6%
10South KoreaUSD 129 mn2.5%USD 312 mn9.2%
11SwedenUSD 73 mn1.4%USD 160 mn8.2%
12PolandUSD 61 mn1.2%USD 135 mn8.2%
13TurkeyUSD 52 mn1.0%USD 114 mn8.2%
14SwitzerlandUSD 43 mn0.8%USD 95 mn8.1%
15NetherlandsUSD 34 mn0.7%USD 75 mn8.3%
16IndiaUSD 29 mn0.6%USD 65 mn8.2%
17AustraliaUSD 24 mn0.5%USD 52 mn8.2%
18BrazilUSD 19 mn0.4%USD 42 mn8.3%
19BelgiumUSD 16 mn0.3%USD 36 mn8.3%
20IrelandUSD 14 mn0.3%USD 32 mn8.4%
21TaiwanUSD 13 mn0.2%USD 28 mn8.0%
22IsraelUSD 11 mn0.2%USD 23 mn8.0%
23DenmarkUSD 8.8 mn0.2%USD 20 mn8.6%
24MexicoUSD 7.7 mn0.1%USD 17 mn8.0%
25AustriaUSD 6.2 mn0.1%USD 14 mn8.9%
Rest of worldUSD 130 mn2.5%USD 284 mn8.1%
Exhibit 5United States and China account for 57% of the USD 6.0 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Liposome market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 5.2 bn. United States: +USD 2.6 bn; China: +USD 786 mn; Japan: +USD 349 mn; Germany: +USD 348 mn; France: +USD 266 mn; 20 other countries: +USD 1.4 bn; Rest of world: +USD 154 mn. Market value 2036: USD 11.1 bn.Market value 20265.2 bnUnited States+2.6 bnChina+786 mnJapan+349 mnGermany+348 mnFrance+266 mn20 other countries+1.4 bnRest of world+154 mnMarket value 203611.1 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Gilead Sciences
  • Johnson and Johnson
  • Pacira BioSciences
  • Jazz Pharmaceuticals
  • Baxter

Group 2: Regional and specialist players

  • Ipsen
  • Sun Pharmaceutical
  • Teva
  • Fresenius Kabi
  • Dr. Reddy's Laboratories
  • Zydus Lifesciences
  • CSPC Pharmaceutical
  • Luye Pharma
  • Sumitomo Pharma

Group 3: Emerging and niche players

  • Lipoid
  • Avanti Polar Lipids
  • Taiwan Liposome Company

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the liposome market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 8.0% is calculated from the resulting values.

The market is divided by drug class, by route, by lipid composition, by application, by development stage. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the liposome market?

The global liposome market is estimated at USD 4.8 bn in 2025 and USD 5.2 bn in 2026.

How fast will the liposome market grow?

It is forecast to reach USD 11.1 bn by 2036, a compound annual growth rate of 8.0% from 2026, an increase of USD 6.0 bn.

Which country is the largest market for liposome?

United States is the largest market by revenue at USD 2.4 bn in 2026, 46.0% of the global total. The three largest countries together hold 62.0%.

Which country is growing fastest?

Among the ten largest markets, China is growing fastest at 12.2% a year from 2026 to 2036.

Which liposome segment is largest?

In the by drug class split, Anticancer is the largest segment with 52.0% of 2026 revenue.

Who are the leading liposome companies?

Global leaders include Gilead Sciences, Johnson and Johnson, Pacira BioSciences, Jazz Pharmaceuticals.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Lateral Flow Assay Liquid Handling →

All Healthcare markets →

Request a sample